Cargando…
Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
Oral cabozantinib tablets (Cabometyx(®)) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated in the development of RCC. The previously approved indicatio...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323107/ https://www.ncbi.nlm.nih.gov/pubmed/30679901 http://dx.doi.org/10.1007/s40267-018-0547-6 |